|
IAC Express 2009 |
| Issue number 801: May 26, 2009 |
|
|
Please click here to subscribe to IAC Express
as well as other FREE IAC periodicals. |
|
Contents
of this Issue
Select a title to jump to the article. |
- HHS
directs $1 billion toward development of vaccine for novel influenza A
(H1N1); new HHS ad campaign planned to encourage the public to protect
itself against H1N1 influenza
- MMWR
reports on antibody response to H1N1 after vaccination with seasonal
influenza vaccine
- MMWR
reports on patients hospitalized with H1N1 influenza
- MMWR
publishes surveillance summary on acute viral hepatitis
- President
Obama appoints Dr. Thomas Frieden as CDC director
- CDC
offers new H1N1 influenza resources in translation
- IAC's
Video of the Week helps healthcare professionals talk to parents about
vaccine concerns
- IAC
revises "Admission Orders for Labor & Delivery and Newborn Units to
Prevent HBV Transmission" and "Standing Orders for Administering Rotavirus
Vaccine to Infants"
- IAC
updates and redesigns "After the shots. . . What to do if your child has
discomfort"
- IAC
updates three print pieces that answer the public's questions about
rotavirus, diphtheria, and Hib
- Mark
your calendar: July 30 is the date for "Immunization Update 2009"
- The 11th
edition of CDC's Pink Book can now be downloaded
- IAC's
laminated versions of the 2009 child/teen and adult immunization schedules
offer significant advantages over paper versions. Place your order today
and use them throughout 2009!
- May
issue of CDC's Immunization Works electronic newsletter recently released
- IZTA
plans June 16 conference call on influenza and June 30 call on making new
media work for immunization coalitions
- MMWR
reports on progressive vaccinia in a military smallpox vaccinee
- Erratum:
MMWR corrects two sentences in its report on H1N1 influenza in pregnant
women
|
| |
| Abbreviations |
|
|
AAFP, American Academy of Family Physicians; AAP,
American Academy of Pediatrics; ACIP, Advisory Committee on Immunization
Practices; AMA, American Medical Association; CDC, Centers for Disease
Control and Prevention; FDA, Food and Drug Administration; IAC, Immunization
Action Coalition; MMWR, Morbidity and Mortality Weekly Report; NCIRD,
National Center for Immunization and Respiratory Diseases; NIVS, National
Influenza Vaccine Summit; VIS, Vaccine Information Statement; VPD,
vaccine-preventable disease; WHO, World Health Organization. |
| |
|
Issue 801: May 26, 2009 |
|
|
|
1. |
HHS directs $1 billion toward development of vaccine for novel influenza A
(H1N1); new HHS ad campaign planned to encourage the public to protect itself
against H1N1 influenza
On May 22, HHS Secretary Kathleen Sebelius
announced that the
department will direct approximately $1 billion toward
development of a vaccine for H1N1 influenza. The press release
is reprinted below in its entirety.
Also, on May 22, HHS issued a press release about a new ad
campaign to encourage the public to protect itself against H1N1
influenza. A link to the press release about the ad campaign is
given at the end of this IAC Express story.
HHS Secretary Kathleen Sebelius announced today that the
department will take important steps necessary to prepare for
potential commercial-scale production of a candidate vaccine for
the novel Influenza A (H1N1). The Secretary is directing
approximately $1 billion in existing funds that will be used for
clinical studies that will take place over the summer and for
commercial-scale production of two potential vaccine ingredients
for the pre-pandemic influenza stockpile.
"Preparation and planning are critical to keep Americans safe in
the face of a potential pandemic," Secretary Sebelius said. "Our
goal throughout this new H1N1 outbreak has been to stay one step
ahead of the virus. An important part of this effort has been
our work to develop a potential vaccine because vaccines can
help prevent and control influenza virus outbreaks. The actions
we are taking today will help us be prepared if a vaccine is
needed."
The funds will be used to place new orders on existing contracts
with companies that hold U.S. licenses for flu vaccines. With
these orders, they will produce a bulk supply of vaccine antigen
and adjuvant. Antigen is the active ingredient in a vaccine that
causes the human body's immune system to develop antibodies that
help fight an invading virus. Depending on the results of
clinical studies, adjuvants could be added to a vaccine to
improve the immune system's response and potentially reduce the
amount of antigen necessary for the body to recognize and fight
a virus.
Having both antigen and adjuvant on hand provides maximum
flexibility in a future immunization program, if a program is
recommended. For example, if needed these ingredients could be
used in vaccine to help protect health providers and other
members of the critical workforce, as recommended by the
National Strategy for Pandemic Influenza.
With these funds manufacturers will also prepare pilot lots of
potential vaccine for use in clinical studies to determine the
proper dose for a vaccine, determine if adjuvants are
appropriate and ensure a vaccine is safe and effective. The U.S.
government will share as much information as possible from the
results of these clinical studies with the World Health
Organization and the global community so that other countries
can benefit from the U.S. efforts to determine dosage, safety
and effectiveness.
The Biomedical Advanced Research and Development Authority
(BARDA) in the HHS Office of the Assistant Secretary for
Preparedness and Response established the existing contracts
with these companies in 2004 as part of the National Strategy
for Pandemic Influenza.
To learn more about the National Strategy for Pandemic
Influenza, visit
http://www.pandemicflu.gov/plan/federal/pandemic-influenza.pdf
More about BARDA is available at
http://www.hhs.gov/aspr/barda/index.html For the latest on the
H1N1 flu virus, see http://www.cdc.gov/h1n1flu
To access the HHS press release about vaccine development, go
to: http://www.hhs.gov/news/press/2009pres/05/20090522b.html
Secretary Sebelius also announced on May 22 that HHS will be
joining the Ad Council and Sesame Workshop, the nonprofit
educational organization behind Sesame Street, to launch a
national public service advertising (PSA) campaign designed to
encourage American families and children to take steps to
protect themselves from the 2009 H1N1 influenza virus. As part
of HHS and the Ad Council's campaign, Sesame Workshop produced a
television PSA featuring Sesame Street's Elmo and Gordon
explaining the importance of healthy habits such as washing your
hands, avoid touching your eyes, nose, and mouth, and sneezing
into the bend of your arm.
To read the HHS press release about this public service
advertising campaign, go to:
http://www.hhs.gov/news/press/2009pres/05/20090522a.html
Back to top |
| |
|
|
2. |
MMWR reports on antibody response to H1N1 after vaccination with seasonal
influenza vaccine
CDC published "Serum Cross-Reactive Antibody
Response to a Novel
Influenza A (H1N1) Virus After Vaccination with Seasonal
Influenza Vaccine" in the May 22 issue of MMWR. The editorial
note follows.
Editorial Note:
The results in this report suggest that vaccination with recent
(2005-2009) seasonal influenza vaccines is unlikely to provide
protection against the novel influenza A (H1N1) virus. Although
vaccination of adults with seasonal trivalent inactivated
influenza vaccine (TIV) generally resulted in a small increase
in antibodies against the novel influenza A (H1N1) virus,
whether such levels of cross-reactive antibody provide any
protection against infection with novel influenza A (H1N1) virus
is unknown. These results are consistent with the substantial
degree of genetic divergence of the novel influenza A (H1N1)
virus of swine origin from recent seasonal human H1N1 viruses;
A/California/04/09 shares only 72%-73% amino acid identity in
the HA1 portion of the hemagglutinin molecule with the seasonal
viruses used in this study. For comparison, the amino acid
sequence identity in the HA1 portion among seasonal vaccine
strains used in this study is 97%-98%.
Although the number of sera from children tested in this
analysis was small, results indicate that U.S. children are
largely serologically naive to the novel influenza A (H1N1)
virus and that vaccination with seasonal TIV or live, attenuated
influenza vaccine (LAIV) does not elicit any measurable level of
cross-reactive antibody to the novel virus. Results among adults
suggest that some degree of preexisting immunity to the novel
H1N1 strains exists, especially among adults aged >60 years. One
possible explanation is that some adults in this age group have
had previous exposure, either through infection or vaccination,
to an influenza A (H1N1) virus that is genetically and
antigenically more closely related to the novel influenza A
(H1N1) virus than are contemporary seasonal H1N1 strains.
Ongoing assessment of the cross-reactive antibody response among
persons in different age groups might identify a particular age
group that would allow further clarification of the cross-reactive serologic response. Development of a strain-specific
vaccine against the novel influenza A (H1N1) virus is needed for
optimal protection against the virus among persons of all ages.
To access a web-text (HTML) version of the complete article, go
to: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5819a1.htm
To access a ready-to-print (PDF) version of this issue of MMWR,
go to: http://www.cdc.gov/mmwr/PDF/wk/mm5819.pdf
To receive a FREE electronic subscription to MMWR (which
includes new ACIP recommendations), go to:
http://www.cdc.gov/mmwr/mmwrsubscribe.html
Back to top |
| |
|
|
3. |
MMWR reports on patients hospitalized with H1N1 influenza
CDC published "Hospitalized Patients with Novel
Influenza A
(H1N1) Virus Infection--California, April-May, 2009" in the May
22 issue of MMWR. The first paragraph follows, excluding
references.
Since April 15 and 17, 2009, when the first two cases of novel
influenza A (H1N1) infection were identified from two southern
California counties, novel influenza A (H1N1) cases have been
documented throughout the world, with most cases occurring in
the United States and Mexico. In the United States, early
reports of illnesses associated with novel influenza A (H1N1)
infection indicated the disease might be similar in severity to
seasonal influenza, with the majority of patients not requiring
hospitalization and only rare deaths reported, generally in
persons with underlying medical conditions. As of May 17, 2009,
553 novel influenza A (H1N1) cases, including 333 confirmed and
220 probable cases, had been reported in 32 of 61 local health
jurisdictions in California. Of the 553 patients, 30 have been
hospitalized. No fatal cases associated with novel influenza A
(H1N1) infection had been reported in California. This report
summarizes the 30 hospitalized cases as of May 17, including a
detailed description of four cases that illustrate the spectrum
of illness severity and underlying risk factors. This
preliminary overview indicates that, although the majority of
hospitalized persons infected with novel influenza A (H1N1)
recovered without complications, certain patients had severe and
prolonged disease. All hospitalized patients with novel
influenza A (H1N1) infection should be monitored carefully and
treated with antiviral therapy, including patients who seek care
>48 hours after illness onset. . . .
To access a web-text (HTML) version of the complete article, go
to: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5819a6.htm
To access a ready-to-print (PDF) version of this issue of MMWR,
go to: http://www.cdc.gov/mmwr/PDF/wk/mm5819.pdf
Back to top |
| |
|
|
4. |
MMWR publishes surveillance summary on acute viral hepatitis
CDC published "Surveillance for Acute Viral
Hepatitis--United
States, 2007" as a MMWR Surveillance Summary on May 22. The
abstract follows.
Abstract
Problem: In the United States, acute viral hepatitis most
frequently is caused by infection with any of three distinct
viruses: hepatitis A virus (HAV), hepatitis B virus (HBV), or
hepatitis C virus (HCV). These unrelated viruses are transmitted
through different routes and have different epidemiologic
profiles. Safe and effective vaccines have been available for
hepatitis B since 1981 and for hepatitis A since 1995. No
vaccine exists against hepatitis C. HBV and HCV can persist as
chronic infections and represent a leading cause of chronic
liver disease and hepatocellular carcinoma in the United States.
Reporting Period Covered: Cases in 2007, the most recent year
for which data are available, are compared with those from
previous years.
Description of System: Cases of acute viral hepatitis are
reported voluntarily to CDC by state and territorial health
departments via CDC's National Notifiable Disease Surveillance
System (NNDSS). Reports are received electronically via CDC's
National Electronic Telecommunications System for Surveillance
(NETSS).
Results: Acute hepatitis A incidence has declined 92%, from 12.0
cases per 100,000 population in 1995 to 1.0 case per 100,000
population in 2007, the lowest rate ever recorded. Declines were
greatest among children and in those states where routine
vaccination of children was recommended beginning in 1999. Acute
hepatitis B incidence has declined 82%, from 8.5 cases per
100,000 population in 1990 to 1.5 cases per 100,000 population
in 2007, the lowest rate ever recorded. Declines occurred among
all age groups but were greatest among children aged <15 years.
Following a peak in 1992, incidence of acute hepatitis C
declined; however, since 2003, rates have plateaued. In 2007, as
in previous years, the majority of these cases occurred among
adults, and injection-drug use was the most common risk factor.
Interpretation: The results documented in this report suggest
that implementation of the 1999 recommendations for routine
childhood hepatitis A vaccination in areas of the United States
with consistently elevated hepatitis A rates has reduced rates
of infection. In addition, universal vaccination of children
against hepatitis B beginning in 1991 has reduced disease
incidence substantially among younger age groups. Higher rates
of hepatitis B continue among adults, particularly among males
aged 30-44 years, reflecting the need to vaccinate adults at
risk for HBV infection. The decline in hepatitis C incidence
after 1992 was attributable primarily to a decrease in incidence
among injection-drug users. The reasons for this decrease were
unknown but probably reflected changes in behavior and practices
among injection-drug users.
Public Health Actions: The expansion in 2006 of recommendations
for routine hepatitis A vaccination to include all children in
the United States aged 12-23 months is expected to reduce
hepatitis A rates further. Ongoing hepatitis B vaccination
programs ultimately will eliminate domestic HBV transmission,
and increased vaccination of adults with risk factors will
accelerate progress toward elimination. Further prevention of
hepatitis B and hepatitis C relies on identifying and preventing
transmission of HBV or HCV in hospital and nonhospital
healthcare associated settings. In addition, prevention of
hepatitis C relies on identifying and counseling uninfected
persons at risk for hepatitis C (e.g., injection-drug users)
regarding ways they can protect themselves from infection.
Public health management of persons with chronic HBV or HCV
infection will help to interrupt the transmission to susceptible
persons, and their medical management will help to reduce the
development of the sequelae from chronic liver disease. . . .
To access a web-text (HTML) version of the complete surveillance
summary, go to:
http://www.cdc.gov/mmwr/preview/mmwrhtml/ss5803a1.htm
To access a ready-to-print (PDF) version of this surveillance
summary, go to:
http://www.cdc.gov/mmwr/PDF/ss/ss5803.pdf
Back to top |
| |
|
|
5. |
President Obama appoints Dr. Thomas Frieden as CDC director
On May 15, President Barack Obama announced that
he had
appointed Thomas Frieden, MD, MPH, currently commissioner of the
New York City Health Department, as director of the Centers for
Disease Control and Prevention.
President Obama also announced that acting CDC director Dr.
Richard Besser, who has led the CDC's Coordinating Office for
Terrorism Preparedness and Emergency Response for the past four
years, will continue in this role.
To read the related White House press release, go to:
http://www.whitehouse.gov/the_press_office/President-Obama-Appoints-Dr-Thomas-Frieden-as-CDC-Director
Back to top |
| |
|
|
6. |
CDC offers new H1N1 influenza resources in translation
CDC now offers two fact sheets on H1N1 influenza
in Spanish,
Arabic, Simplified Chinese, French, and Russian as well as
English. The fact sheets are titled "Key Facts About Swine Flu"
and "H1N1 (Swine Flu) and You." For sources of continually
updated H1N1 influenza information, see the end of this IAC
Express article.
To access the English version of "Key Facts About Swine
Influenza," go to:
http://www.cdc.gov/h1n1flu/key_facts.htm
To access the Spanish version of "Key Facts About Swine
Influenza," go to:
http://www.cdc.gov/h1n1flu/espanol/datos.htm
To access the Arabic version of "Key Facts About Swine
Influenza," go to:
http://www.cdc.gov/h1n1flu/Arabic/key_facts_AR.pdf
To access the Chinese version of "Key Facts About Swine
Influenza," go to:
http://www.cdc.gov/h1n1flu/Simplified_Chinese/key_facts_SCH.pdf
To access the French version of "Key Facts About Swine
Influenza," go to:
http://www.cdc.gov/h1n1flu/Francais/key_facts_FR.pdf
To access the Russian version of "Key Facts About Swine
Influenza," go to:
http://www.cdc.gov/h1n1flu/Russian/key_facts_RU.pdf
To access the English version of "H1N1 Flu (Swine Flu) and You,"
go to:
http://www.cdc.gov/h1n1flu/qa.htm
To access the Spanish version of "H1N1 Flu (Swine Flu) and You,"
go to:
http://www.cdc.gov/h1n1flu/espanol/influenza-porcina-y-usted.htm
To access the Arabic version of "H1N1 Flu (Swine Flu) and You,"
go to:
http://www.cdc.gov/h1n1flu/Arabic/qa_AR.pdf
To access the Chinese version of "H1N1 Flu (Swine Flu) and You,"
go to:
http://www.cdc.gov/h1n1flu/Simplified_Chinese/qa_SCH.pdf
To access the French version of "H1N1 Flu (Swine Flu) and You,"
go to:
http://www.cdc.gov/h1n1flu/Francais/qa_FR.pdf
To access the Russian version of "H1N1 Flu (Swine Flu) and You,"
go to:
http://www.cdc.gov/h1n1flu/Russian/qa_RU.pdf
SOURCES OF CONTINUALLY UPDATED INFORMATION
The home page of CDC's H1N1 Flu web section can be accessed from
http://www.cdc.gov/h1n1flu
Interim guidance documents from CDC can be accessed directly
from http://www.cdc.gov/H1N1flu/guidance
IAC has gathered important information related to H1N1 influenza
in a new web section to make it easier to keep up to date with
developments. To access this resource, go to:
http://www.immunize.org/h1n1
Back to top |
| |
|
|
7. |
IAC's Video of the Week helps healthcare professionals talk to parents about
vaccine concerns
IAC's Video of the Week is a webcast from the
California
Immunization Coalition (CIC) that deals with parents' concerns
about vaccine safety. The video is intended for health
professionals, and features a panel that includes physicians,
scientists, a communications expert, public health
professionals, and parents. The panel advises a mother whose
child is scheduled to receive a vaccine the next day.
The video will be available on the home page of IAC's website
through May 31. To access it, go to: http://www.immunize.org and
click on the image under the words Video of the Week, which
you'll find toward the top of the page. It may take a few
moments for the video to begin playing; please be patient!
Remember to bookmark IAC's home page to view a new video every
Monday. While you're at our home page, we encourage you to
browse around--you're sure to find resources and information
that will enhance your practice's immunization delivery.
All the videos featured as an IAC Video of the Week have
recently been archived in a new section of IAC's website. To
view any of the videos previously featured, go to:
http://www.immunize.org/votw/apr09.asp
Back to top |
| |
|
|
8. |
IAC
revises "Admission Orders for Labor & Delivery and Newborn Units to Prevent HBV
Transmission" and "Standing Orders for Administering Rotavirus Vaccine to
Infants"
IAC has made many small changes to its 2-page
piece for
healthcare professionals, "Admission Orders for Labor & Delivery
and Newborn Units to Prevent Hepatitis B Virus (HBV)
Transmission" (formerly "Guidelines for Standing Orders in Labor
& Delivery and Nursery Units to Prevent Hepatitis B Virus
Transmission to Newborns"). The piece also now includes sample
text for an admission order for routine newborn hepatitis B
vaccination.
To access the revised "Admission Orders for Labor & Delivery and
Newborn Units to Prevent Hepatitis B Virus (HBV) Transmission,"
go to: http://www.immunize.org/catg.d/p2130.pdf
IAC has also updated "Standing Orders for Administering
Rotavirus Vaccine to Infants." Changes include clarification of
step #4 (changing "dosing tube" to "dosing applicator" and
noting that Rotarix needs to be reconstituted and RotaTeq does
not), and changing the last date for administering rotavirus
vaccine from "before age 8 months 0 days" to "by age 8 months 0
days."
To access the revised "Standing Orders for Administering
Rotavirus Vaccine to Infants," go to:
http://www.immunize.org/catg.d/p3087.pdf
To access a table with links to all of IAC's standing orders
protocols for vaccine administration and medical management of
vaccine reactions, go to: http://www.immunize.org/standingorders
Back to top |
| |
|
|
9. |
IAC
updates and redesigns "After the shots. . . What to do if your child has
discomfort"
IAC has updated its parent piece, "After the
shots. . . What to
do if your child has discomfort." The piece includes medicines
and dosages for reducing pain and fever and features a new look.
To access the revised "After the shots. . . What to do if your
child has discomfort, go to:
http://www.immunize.org/catg.d/p4015.pdf
IAC's Print Materials web section offers healthcare
professionals and the public approximately 250 FREE English-language materials (many also available in translation), which
we encourage website users to print out, copy, and distribute
widely. To access all of IAC's free print materials, go to:
http://www.immunize.org/printmaterials
Back to top |
| |
|
|
10. |
IAC updates three print pieces that answer the public's questions about
rotavirus, diphtheria, and Hib
IAC recently revised three of its Q&A
patient-education print
pieces: "Rotavirus: Questions and Answers," "Diphtheria:
Questions and Answers," and "Haemophilus influenzae type b
(Hib): Questions & Answers." All were updated to incorporate
changes recently made in vaccine recommendations and licensure.
The revised pieces are ready-to-print versions of some of the
CDC-reviewed material located on IAC's Vaccine Information
website (www.vaccineinformation.org). The website is intended
for the public, health professionals, and the media.
To access the revised ready-to-print (PDF) print piece
"Rotavirus: Questions and Answers," go to:
http://www.immunize.org/catg.d/p4217.pdf
To view an HTML version of these Q&As, go to the following:
(1) Rotavirus disease:
http://www.vaccineinformation.org/rotavirus/qandadis.asp
(2) Rotavirus vaccine:
http://www.vaccineinformation.org/rotavirus/qandavax.asp
To access the revised ready-to-print (PDF) print piece
"Diphtheria: Questions and Answers," go to:
http://www.immunize.org/catg.d/p4203.pdf
To view an HTML version of these Q&As, go to the following:
(1) Diphtheria disease:
http://www.vaccineinformation.org/diphther/qandadis.asp
(2) Diphtheria vaccine:
http://www.vaccineinformation.org/diphther/qandavax.asp
To access the revised ready-to-print (PDF) print piece
"Haemophilus influenzae type b (Hib): Questions & Answers," go
to:
http://www.immunize.org/catg.d/p4206.pdf
To view an HTML version of these Q&As, go to the following:
(1) Hib disease:
http://www.vaccineinformation.org/hib/qandadis.asp
(2) Hib vaccine:
http://www.vaccineinformation.org/hib/qandavax.asp
To access Q&As about other diseases and vaccines in PDF format,
go to:
http://www.immunize.org/printmaterials/questions.asp
Back to top |
| |
|
|
11. |
Mark your calendar: July 30 is the date for "Immunization Update 2009"
July 30 is the date for this year's highly
anticipated
"Immunization Update," presented by CDC experts. The 2009 course
instructors include William L. Atkinson, MD, MPH; Donna L.
Weaver, RN, MN; Andrew T. Kroger, MD, MPH; Iyabode Akinsanya-Beysolow, MD, MPH, FAAP; and guest experts.
This live satellite broadcast and webcast will provide up-to-date information on the rapidly changing field of immunization.
Anticipated topics include influenza (including H1N1 influenza),
rotavirus, vaccine safety, and vaccine supply. So-called
"alternative" vaccine schedules and other emerging vaccine
issues will also be discussed.
The 2.5-hour broadcast will occur live from 9:00 to 11:30 AM and
will be re-broadcast that day from 12:00 noon to 2:30 PM
(Eastern Time). Both broadcasts will feature a live question-and-answer session in which participants nationwide can interact
with the course instructors via toll-free telephone lines.
To register to attend the broadcast at a specific location, or
to search for available locations, visit the CDC/ATSDR Training
and Continuing Education Online System at
http://www2a.cdc.gov/TCEOnline Site registration begins on June
4, 2009. Individual registration begins on July 16, 2009. For
questions about registration, call (800)418-7246 or email
ce@cdc.gov
Note: You do not need to register to participate in the webcast.
The webcast will be available online for one month following the
broadcast at http://www2a.cdc.gov/phtn/webcast/immupdate2009
For additional questions regarding program content, please email
nipinfo@cdc.gov
Back to top |
| |
|
|
12. |
The 11th edition of CDC's Pink Book can now be downloaded
CDC's Pink Book, formally titled "Epidemiology
and Prevention of
Vaccine-Preventable Diseases," has been updated and the 11th
edition is now available for reading or downloading online.
To download chapter files of the Pink Book in PDF format, go to
the chapter index at
http://www.cdc.gov/vaccines/pubs/pinkbook/pink-chapters.htm
For information about ordering a print copy, go to:
http://www.cdc.gov/vaccines/pubs/pinkbook/#order
Back to top |
| |
|
|
13. |
IAC's laminated versions of the 2009 child/teen and adult immunization
schedules offer significant advantages over paper versions. Place your order
today and use them throughout 2009!
IAC's 2009 laminated immunization schedules are a
must for every
immunization setting: from conventional health clinics and
private practices to walk-in shot clinics in workplaces,
pharmacies, schools, and other sites. IAC offers the laminated
schedules for two age groups. The child/teen immunization
schedule is for people ages 0 through 18 years; the adult
schedule is for those older than 18. Though both are adapted
from the immunization schedules that were posted on the CDC
website in January, the laminated schedules offer these
advantages over downloadable paper versions:
-
Coated in thick plastic, the laminated schedules
are washable and will hold up to a year's worth of use as teaching tools that
providers in any immunization setting can use to give patients and parents
authoritative information about the vaccines recommended for various age
groups. You can also use them as a handy reference to consult at a moment's
notice.
-
For the second year in a row, IAC has added a significant
feature to the two laminated schedules. Each includes a guide to
contraindications and precautions for the pertinent age group
(i.e., the child/teen schedule has a guide to contraindications
and precautions for child/teen vaccines, and the adult schedule
has a guide for adult vaccines). Healthcare professionals will
find these guides extremely valuable in making an on-the-spot
determination about vaccinating any patient they see in any
immunization setting.
The durable laminated schedules come complete with essential
footnotes and are printed in color for easy reading. Each
schedule has six pages (i.e., three double-sided pages), and
when folded, measures 8.5" x 11".
For specific information about the child/teen schedule, to view
images of it, or to order online or download an order form,
visit http://www.immunize.org/shop/schedule_child.asp
For specific information about the adult schedule, to view
images of it, or to order online or download an order form,
visit http://www.immunize.org/shop/schedule_adult.asp
Prices start at $10 each for 1-4 copies and drop to $6.50 each
for 5-19 copies. Discount pricing is available for 20 or more
copies. For quotes on customizing or placing orders in excess of
999 schedules, call (651) 647-9009 or email
admininfo@immunize.org
To learn about other essential immunization resources available
for purchase from IAC, go to: http://www.immunize.org/shop
Back to top |
| |
|
|
14. |
May issue of CDC's Immunization Works electronic newsletter recently released
CDC recently released the May issue of its
monthly newsletter
Immunization Works; it is posted on the website of the National
Center for Immunization and Respiratory Diseases (NCIRD). The
newsletter offers the immunization community information about
current topics. The information is in the public domain and can
be reproduced and circulated widely.
Some of the information in the May issue has already appeared in
previous issues of IAC Express. Following is the text of some
articles we have not covered.
FRONT PAGE NEWS
MORE NOVEL H1N1 NEWS: Novel influenza A (H1N1) activity is now
being detected through CDC's routine influenza surveillance
systems and reported weekly in FluView. The fact that novel H1N1
activity is now detected through seasonal surveillance systems
is an indication that there are higher levels of influenza-like
illness in the United States than is normal for this time of
year. About half of all influenza viruses being detected through
laboratory surveillance are novel H1N1 viruses.
As of May 18th, 5 deaths and 5,123 confirmed and probable cases
of novel H1N1 influenza have been reported in the United States
and the District of Columbia. Recently, CDC began reporting
numbers of confirmed and probable cases of novel H1N1 infection
by state as an aggregate, or total. This is because almost all
probable cases that have undergone further testing have been
found to be the novel H1N1 virus. Reporting aggregate probable
and confirmed cases will better reflect the true impact of novel
H1N1 flu on the United States. The list of states with the
numbers of confirmed and probable cases of novel H1N1 infection
is available online and updated Monday-Friday at about 11:00 AM
at CDC's H1N1 Flu (Swine Flu) website
(http://www.cdc.gov/h1n1flu). This site also contains links to
resources for specific groups, such as clinicians, pregnant
women, and travelers, as well as CDC's Spanish Language H1N1 Flu
website (http://www.cdc.gov/h1n1flu/espanol).
It's important that people continue to take steps to protect
their health and the health of their family. Personal health
message should continue to reinforce the following:
- Cover your nose and mouth with a tissue when you cough or
sneeze. Throw the tissue in the trash after you use it.
- Wash your hands often with soap and water, especially after
you cough or sneeze.
- Alcohol-based hand cleaners are also effective.
- Avoid touching your eyes, nose or mouth.
- If you are sick, stay home for 7 days after your symptoms
begin or until you have been symptom-free for 24 hours,
whichever is longer.
For the latest information about the novel H1N1 outbreak, sign
up to receive CDC email updates, subscribe to RSS, or follow CDC
Emergency on Twitter. Updated world-wide country counts can be
found at the World Health Organization website
(http://www.who.int/en).
OTHER NEWS AND SUMMARIES
WHAT DO MEDICAL ASSISTANTS NEED TO KNOW ABOUT VACCINES? A new
report focuses on the immunization training needs of medical
assistants (http://www.aptrweb.org/resources/assistants.html).
Summarizing the results of a survey conducted in 2008 by Emory
University through a Cooperative Agreement between the
Association for Prevention Teaching and Research (APTR) and
NCIRD, CDC, the report describes the immunization tasks medical
assistants frequently perform, their experiences with
immunization-related training, their preferences for training
topics and delivery methods, and barriers to training. Study
results will be used to improve the educational offerings to
this group of health professionals.
MEETINGS, CONFERENCES & RESOURCES
2010 NATIONAL COALITION CONFERENCE: Please mark your calendars
for the 9th National Conference on Immunization and Health
Coalitions "Strengthening Our Connections." The conference will
take place from May 26–28 in Chicago, Illinois. More information
will be available in future issues of this publication.
RESPIRATORY NEWS AND RESOURCES
GET SMART ABOUT ANTIBIOTICS WEEK: Mark your calendars for "Get
Smart about Antibiotics Week", October 5-11, 2009.
Issues of Immunization Works are posted on CDC's Vaccines &
Immunizations website a few days after publication. To access
the May issue, go to:
http://www.cdc.gov/vaccines/news/newsltrs/imwrks/2009/200905.htm
Back to top |
| |
|
|
15. |
IZTA
plans June 16 conference call on influenza and June 30 call on making new media
work for immunization coalitions
The Immunization Coalitions Technical Assistance
Network (IZTA)
has two conference calls scheduled in June. Details on each
follow.
JUNE 16 CALL ON INFLUENZA:
Dr. L.J Tan, MS, PhD, will present his annual engaging and
informative influenza update during this call, including the
latest research from the 2008-09 season and predictions and
plans for the 2009-10 influenza season.
The June 16 call will be held at 1PM, ET. To sign up, send an
email to izta@aed.org with the subject line "Sign me up for the
Influenza Update Call."
JUNE 30 CALL ON MAKING NEW MEDIA WORK FOR IMMUNIZATION
COALITIONS:
This call will discuss the ins and outs of new media and how
these applications can help your coalition. Web expert Shea Van
Horn will describe new technologies such as social networking
sites, RSS feeds, blogging, and video sharing. Jennifer Bailey
and Edgar Ednacot from the California Department of Public
Health will discuss their state's new "I Choose" campaign that
uses new media technologies to promote vaccination.
The June 30 call will be held at 1PM, ET. To sign up, send an
email to izta@aed.org with the subject line "Sign me up for the
Web 2.0 call."
IZTA is a program of the Center for Health Communication,
Academy for Educational Development.
To access earlier programs, go to:
http://www.izta.org/confcall.cfm
Back to top |
| |
|
|
16. |
MMWR reports on progressive vaccinia in a military smallpox vaccinee
CDC published "Progressive Vaccinia in a Military
Smallpox
Vaccinee--United States, 2009" in the May 22 issue of MMWR. The
first paragraph is reprinted below, excluding references.
Progressive vaccinia (PV), previously known as vaccinia
necrosum, vaccinia gangrenosum, or disseminated vaccinia, is a
rare, often fatal adverse event after vaccination with smallpox
vaccine, which is made from live vaccinia virus. During recent
vaccination programs potential cases of PV were investigated,
but none met standard case definitions. PV has not been
confirmed to have occurred in the United States since 1987. On
March 2, 2009, a U.S. Navy Hospital contacted the Poxvirus
Program at CDC to report a possible case of PV in a male
military smallpox vaccinee. The service member had been newly
diagnosed with acute mylegenous leukemia M0 (AML M0). During
evaluation for a chemotherapy-induced neutropenic fever, he was
found to have an expanding and nonhealing painless vaccination
site 6.5 weeks after receipt of smallpox vaccine. Clinical and
laboratory investigation confirmed that the vaccinee met the
Brighton Collaboration and CDC adverse event surveillance
guideline case definition for PV. This report summarizes the
patient's protracted clinical course and the military and
civilian interagency governmental, academic, and industry public
health contributions to his complex medical management. The
quantities of investigational and licensed therapeutics and
diagnostics used were greater than anticipated based on existing
smallpox preparedness plans. To support future public health
needs adequately, the estimated national supply of therapeutics
and diagnostic resources required to care for smallpox vaccine
adverse events should be reevaluated. . . .
To access a web-text (HTML) version of the complete article,
including references and photos, go to:
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5819a5.htm
To access a ready-to-print (PDF) version of this issue of MMWR,
go to:
http://www.cdc.gov/mmwr/PDF/wk/mm5819.pdf
Back to top |
| |
|
|
17. |
Erratum: MMWR corrects two sentences in its report on H1N1 influenza in
pregnant women
CDC published "Errata: Vol. 58, No. 18" in the
May 22 issue of
MMWR. The article follows in its entirety.
In the report, "Novel Influenza A (H1N1) Virus Infections in
Three Pregnant Women--United States, April-May 2009," on page
498, the second and third sentences in the first complete
paragraph should read as follows: "The specimen was forwarded to
the Virus Surveillance and Diagnostic Branch Laboratory,
Influenza Division, CDC, where it could not be confirmed as
novel influenza A (H1N1) virus. On April 30, a repeat
nasopharyngeal specimen and sputum specimen were collected that
were both positive by rRT-PCR for novel influenza A (H1N1) virus
at CDC."
To access a web-text (HTML) version of the complete article, go
to:
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5819a8.htm
To access a ready-to-print (PDF) version of this issue of MMWR,
go to:
http://www.cdc.gov/mmwr/PDF/wk/mm5819.pdf
Back to top |
| |
|
|
